Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Int J Mol Sci (2020) 21:6791
While originally developed for type 2 diabetes, these medications are now frontline treatments for chronic weight management
article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)
Side effects are rare but may include mood swings and higher body temperatures
Contact our research team
Create a concise, written timeline of your symptoms, specifically noting when they began or worsened in relation to your living or working environments
US$ 20.46
US$ 29.35
US$ 27.36
US$ 25.55
US$ 23.31
